Diabetes Research Centre

Diabetes Research Centre

Melbourne, Australia

 

What is Diabetes?

 

Clinical Trials

 

In the Lab

 

Links

 

Contacts

 

Site History

 

Bcl-2 protection of islet allografts is unmasked by costimulation blockade

R.M. Sutherland, J. L. Brady, A.M. Lew, in collaboration with J. Allison, Department of Microbiology and Immunology, University of Melbourne; H.E. Thomas and T.W.H. Kay, St. Vincent’s Institute of Medical Research, Melbourne

Pancreatic islet transplantation may cure type 1 diabetes but there are insufficient islet donors. Furthermore, side-effects of immunosuppressive drugs preclude transplants into patients whose diabetes is controlled by parenteral insulin. We hypothesised that overexpressing anti-apoptotic Bcl-2 or secretion of immunomodulatory CTLA4Ig molecules in islet beta cells would enhance survival of transplanted islets whilst minimizing systemic side-effects. Although Bcl-2 overexpression alone was insufficient in protecting mouse islet allografts from rejection, its beneficence was shown by enhanced protection when the adaptive immune response was inhibited by locally produced CTLA4Ig. Thus, combined anti-apoptotic and immunosuppressive intervention may reduce the level of systemic immunosuppression or quantity of donor tissue required.

 

Activated macrophages require T cells for traffic to transplant tissues

Y. Zhan, J. L. Brady, A.M. Lew, in collaboration with W. Irawaty, H.E. Thomas and T.W.H. Kay, St. Vincent’s Institute of Medical Research, Melbourne

Although macrophage activation by T cells is critical for the xenograft rejection, we found that activated macrophages in the absence of T cells were unable to reject xenografts under the kidney capsule, although they rejected xenogeneic cells in the peritoneal cavity (with an abundance of resident macrophages). This implies that activated macrophages self-recruit inefficiently to peripheral graft sites. T-cell transfer resulted in the rejection of xenogeneic cells at both the kidney capsule and peritoneal sites. These results argue that activated macrophages (as the result of T-cell activation) still require T cells for xenograft rejection at peripheral sites.

 

Return to Immune Mechanisms

 

 

 

 

 

 

Diabetes Research Centre

Last updated 19 December, 2007. For further information about this website, please contact Catherine McLean